Gland Pharma Limited
GLAND.BO
Get informed when a big investor buys or sells
+ FollowMarket Cap$505.07B
Close$
Share Statistics
| Market cap | $505.07 Billion |
|---|---|
| Enterprise Value | $505.07 Billion |
| Dividend Yield | $38.00 (0.65%) |
| Earnings per Share | $62.35 |
| Beta | 0.49 |
| Outstanding Shares | 164,825,000 |
Return
| Return on Equity | 10.90% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 44.69 |
|---|---|
| PEG | 94.9 |
| Price to Sales | 7.51 |
| Price to Book Ratio | 4.88 |
| Enterprise Value to Revenue | 7.51 |
| Enterprise Value to EBIT | 32.55 |
| Enterprise Value to Net Income | 44 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$18.01
Average shareholder expectationRevenue Estimate
$17.45 B
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$16.60
Average shareholder expectationRevenue Estimate
$17.30 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Gland Pharma Limited
4,332 employees
CEO: Shyamakant Giri Gland Pharma Limited specializes in the production and global distribution of injectable pharmaceutical formulations, with significant markets spanning India, the United States, Europe, Canada, Australia, and New Zealand. The company act...